RJA
QTTB icon

Raymond James & Associates’s Q32 Bio QTTB Stock Holding History

Raymond James & Associates’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-718
Closed -$7.86K – 4058
2023
Q4 		$7.86K Sell
718
-166
-19% -$2.43K ﹤0.01% 3810
2023
Q3 		$18.6K Hold
884
– – ﹤0.01% 3739
2023
Q2 		$14.1K Hold
884
– – ﹤0.01% 3794
2023
Q1 		$16.4K Hold
884
– – ﹤0.01% 3808
2022
Q4 		$20.1K Sell
884
-53
-6% -$1.41K ﹤0.01% 3795
2022
Q3 		$27K Hold
937
– – ﹤0.01% 3769
2022
Q2 		$33K Hold
937
– – ﹤0.01% 3837
2022
Q1 		$51K Buy
+937
New +$58.2K ﹤0.01% 3909

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James & Associates's QTTB Position: Q1 2024 in Review

Raymond James & Associates sold out of Q32 Bio (QTTB) in Q1 2024, closing a stake of 718 shares — an estimated $7.86K sold.

Raymond James & Associates first reported a position in QTTB in Q1 2022 and held it in 8 quarters. The position peaked at $51K in Q1 2022. 39 funds tracked by Wall St. Rank hold QTTB as of Q1 2024.

  • Raymond James & Associates reported no remaining Q32 Bio position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 718 Q32 Bio shares in Q1 2024, an estimated $7.86K.
  • Raymond James & Associates first reported a position in Q32 Bio in Q1 2022 and held it in 8 quarters.
  • Raymond James & Associates's Q32 Bio position peaked at $51K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.